(Circulation. 2006;113:1272-1274.)
© 2006 American Heart Association, Inc.
Editorial |
From the Divisions of Cardiovascular Medicine and Research, St Elizabeths Medical Center, Boston, Mass.
Correspondence to Douglas W. Losordo, MD, Division of Cardiovascular Research and Medicine, St Elizabeths Medical Center, 736 Cambridge St, Boston, MA, 02135. E-mail douglas.losordo@tufts.edu
Key Words: Editorials angiogenesis cells infarction cell therapy
An extract of the first 250 words of the full text is provided, because this article has no abstract. |
In 1960, McCulloch and Till1 identified a bone marrow stem cell capable of reconstituting hematopoiesis in mice, later documenting the clonality of these cells.2 The concept of the adult stem cell thus was born.
More than 3 decades later, Asahara et al3 extended this concept to include the formation of vascular elements from bone marrowderived, circulating endothelial progenitors. Although controversial at the outset, the endothelial progenitor cell, or EPC, has now established itself within the lexicon of cardiology: At the 2005 Scientific Sessions of the American Heart Association, more than 100 abstracts contained the words "stem cell" in the title and an additional 75 contained the term EPC.4
Article p1287
The escalating interest in stem cells within cardiovascular medicine could be said to be the result of a growing body of evidence that suggests that stem cells may represent therapeutic entities. More than this, however, the concept of stem cell therapy has generated excitement by challenging the long-held paradigm that the heart cannot be repaired. In classic experiments in the laboratory of John Ross in the 1970s (Maroko et al5 and Ginks et al6), the extent of myocardial necrosis was shown to be inextricably linked to the time of coronary occlusion. These studies were not only critical in driving forward the field of reperfusion therapy but also were taken to indicate that the fate of the myocardium was irreversibly determined by this single factor.5,6 The field of cardiac stem cell therapy has reopened this question and ignited interest
This article has been cited by other articles:
![]() |
H. Q. Ly, K. Hoshino, I. Pomerantseva, Y. Kawase, R. Yoneyama, Y. Takewa, A. Fortier, S. L. Gibbs-Strauss, C. Vooght, J. V. Frangioni, et al. In vivo myocardial distribution of multipotent progenitor cells following intracoronary delivery in a swine model of myocardial infarction Eur. Heart J., December 1, 2009; 30(23): 2861 - 2868. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. J. Gersh, R. D. Simari, A. Behfar, C. M. Terzic, and A. Terzic Cardiac Cell Repair Therapy: A Clinical Perspective Mayo Clin. Proc., October 1, 2009; 84(10): 876 - 892. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Higuchi, M. Anton, K. Dumler, S. Seidl, J. Pelisek, A. Saraste, A. Welling, F. Hofmann, R. A.J. Oostendorp, B. Gansbacher, et al. Combined Reporter Gene PET and Iron Oxide MRI for Monitoring Survival and Localization of Transplanted Cells in the Rat Heart J. Nucl. Med., July 1, 2009; 50(7): 1088 - 1094. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Willmann, R. Paulmurugan, M. Rodriguez-Porcel, W. Stein, T. J. Brinton, A. J. Connolly, C. H. Nielsen, A. M. Lutz, J. Lyons, F. Ikeno, et al. Imaging Gene Expression in Human Mesenchymal Stem Cells: From Small to Large Animals Radiology, July 1, 2009; 252(1): 117 - 127. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Q. Ly and S. Nattel Stem Cells Are Not Proarrhythmic: Letting the Genie out of the Bottle Circulation, April 7, 2009; 119(13): 1824 - 1831. [Full Text] [PDF] |
||||
![]() |
E. A. Silva, E.-S. Kim, H. J. Kong, and D. J. Mooney Material-based deployment enhances efficacy of endothelial progenitor cells PNAS, September 23, 2008; 105(38): 14347 - 14352. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. Plotnikov, I. Shlapakova, M. J. Szabolcs, P. Danilo Jr, B. H. Lorell, I. A. Potapova, Z. Lu, A. B. Rosen, R. T. Mathias, P. R. Brink, et al. Xenografted Adult Human Mesenchymal Stem Cells Provide a Platform for Sustained Biological Pacemaker Function in Canine Heart Circulation, August 14, 2007; 116(7): 706 - 713. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Fujimoto, K. Tobita, W. D. Merryman, J. Guan, N. Momoi, D. B. Stolz, M. S. Sacks, B. B. Keller, and W. R. Wagner An Elastic, Biodegradable Cardiac Patch Induces Contractile Smooth Muscle and Improves Cardiac Remodeling and Function in Subacute Myocardial Infarction J. Am. Coll. Cardiol., June 12, 2007; 49(23): 2292 - 2300. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. T. Hirsch Critical Limb Ischemia and Stem Cell Research: Anchoring Hope With Informed Adverse Event Reporting Circulation, December 12, 2006; 114(24): 2581 - 2583. [Full Text] [PDF] |
||||
![]() |
R. Zhou, P. D. Acton, and V. A. Ferrari Imaging Stem Cells Implanted in Infarcted Myocardium J. Am. Coll. Cardiol., November 21, 2006; 48(10): 2094 - 2106. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Rosen Are Stem Cells Drugs?: The Regulation of Stem Cell Research and Development Circulation, October 31, 2006; 114(18): 1992 - 2000. [Abstract] [Full Text] [PDF] |
||||
![]() |
No Long-Term Benefit of Post-MI Bone Marrow Cell Transfer Journal Watch Cardiology, May 11, 2006; 2006(511): 4 - 4. [Full Text] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2006 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |